Kesharwani S - Search Results

1

The Use of Global Sensitivity Analysis to Assess the Oral Absorption of Weakly Basic Compounds: A Case Example of Dipyridamole.

Kesharwani SS, Louit G, Ibrahim F. Kesharwani SS, et al. Pharm Res. 2024 Mar 27. doi: 10.1007/s11095-024-03688-0. Online ahead of print. Pharm Res. 2024. PMID: 38538971

2

A review on accelerated orthodontics.

Nadkerny V, Singh GB, Chhaya B, Dubey R, Kesharwani S, Singh A, Singh Makkad R. Nadkerny V, et al. Among authors: kesharwani s. Bioinformation. 2023 Jan 31;19(1):126-132. doi: 10.6026/97320630019126. eCollection 2023. Bioinformation. 2023. PMID: 37720296 Free PMC article.

3

Crystal structures of non-uracil ring fragments in complex with Mycobacterium tuberculosis uracil DNA glycosylase (MtUng) as a starting point for novel inhibitor design: A case study with the barbituric acid fragment.

Kesharwani S, Raj P, Paul A, Roy K, Bhanot A, Mehta A, Gopal A, Varshney U, Gopal B, Sundriyal S. Kesharwani S, et al. Eur J Med Chem. 2023 Oct 5;258:115604. doi: 10.1016/j.ejmech.2023.115604. Epub 2023 Jun 28. Eur J Med Chem. 2023. PMID: 37399710

4

A Combined In-Vitro and GastroPlus® Modeling to Study the Effect of Intestinal Precipitation on Cinnarizine Plasma Profile in a Fasted State.

Kesharwani SS, Ibrahim F. Kesharwani SS, et al. AAPS PharmSciTech. 2023 May 12;24(5):121. doi: 10.1208/s12249-023-02577-w. AAPS PharmSciTech. 2023. PMID: 37173520

5

A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer.

Kumar H, Gupta NV, Jain R, Madhunapantula SV, Babu CS, Kesharwani SS, Dey S, Jain V. Kumar H, et al. Among authors: kesharwani ss. J Adv Res. 2023 Dec;54:271-292. doi: 10.1016/j.jare.2023.02.005. Epub 2023 Feb 14. J Adv Res. 2023. PMID: 36791960 Free PMC article. Review.

6

Identification of a new and diverse set of Mycobacterium tuberculosis uracil-DNA glycosylase (MtUng) inhibitors using structure-based virtual screening: Experimental validation and molecular dynamics studies.

Raj P, Selvam K, Roy K, Mani Tripathi S, Kesharwani S, Gopal B, Varshney U, Sundriyal S. Raj P, et al. Among authors: kesharwani s. Bioorg Med Chem Lett. 2022 Nov 15;76:129008. doi: 10.1016/j.bmcl.2022.129008. Epub 2022 Sep 27. Bioorg Med Chem Lett. 2022. PMID: 36174837

7

Second Episode of Fever as a Sentinel Event in COVID 19 a Retrospective and Prospective Observational Study.

Kumar D, Lalchandani J, Adsul B, Chavan S, Kumbhar M, Kaimaparambhi V, Chandralekha S, Jha A, Gude O, Kesharwani S, Shaikh S, Nayak O, Singh S, Vachhani H, Valvi R. Kumar D, et al. Among authors: kesharwani s. J Assoc Physicians India. 2021 Jul;69(7):11-12. J Assoc Physicians India. 2021. PMID: 34431282 No abstract available.

8

Design and evaluation of cabazitaxel loaded NLCs against breast cancer cell lines.

Chand P, Kumar H, Badduri N, Gupta NV, Bettada VG, Madhunapantula SV, Kesharwani SS, Dey S, Jain V. Chand P, et al. Among authors: kesharwani ss. Colloids Surf B Biointerfaces. 2021 Mar;199:111535. doi: 10.1016/j.colsurfb.2020.111535. Epub 2020 Dec 14. Colloids Surf B Biointerfaces. 2021. PMID: 33360926

9

Non-hydroxamate inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase (DXR): A critical review and future perspective.

Kesharwani S, Sundriyal S. Kesharwani S, et al. Eur J Med Chem. 2021 Mar 5;213:113055. doi: 10.1016/j.ejmech.2020.113055. Epub 2020 Dec 1. Eur J Med Chem. 2021. PMID: 33303239 Review.

10

Formulation and Nanotechnology-Based Approaches for Solubility and Bioavailability Enhancement of Zerumbone.

Kesharwani SS, Bhat GJ. Kesharwani SS, et al. Medicina (Kaunas). 2020 Oct 23;56(11):557. doi: 10.3390/medicina56110557. Medicina (Kaunas). 2020. PMID: 33114101 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page